FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MCKEON BRIAN P 		2. Issuer Name and Ticker or Trading Symbol

IDEXX LABORATORIES INC /DE [ IDXX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Executive VP, CFO & Treasurer
(Last)          (First)          (Middle)

ONE IDEXX DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/14/2015
(Street)

WESTBROOK, ME 04092
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/14/2015     M    363   A $0   14562   D    
Common Stock   2/14/2015     F    117   D $159.08   14445   D    
Common Stock   2/17/2015     M    5000   A $29.27   19445   D    
Common Stock   2/17/2015     S (1)    2000   D $156.4366   (2) 17445   D    
Common Stock   2/17/2015     S (1)    3000   D $157.3627   (3) 14445   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy)   $159.08   2/14/2015     A      18108         (4) 2/13/2025   Common Stock   18108   $0   18108   D    
Incentive Stock Option (right to buy)   $159.08   2/14/2015     A      628         (5) 2/13/2025   Common Stock   628   $0   628   D    
Restricted Stock Unit     (6) 2/14/2015     A      1572         (6)   (6) Common Stock   1572   $0   9027   D    
Restricted Stock Unit     (7) 2/14/2015     M         363      (7)   (7) Common Stock   363   $0   8664   D    
Non-Qualified Stock Option (right to buy)   $29.27   2/17/2015     M         5000      (8) 5/17/2015   Common Stock   5000   $0   0   D    

Explanation of Responses:
( 1)  The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/20/2014.
( 2)  The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.91 to $156.84, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
( 3)  The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.91 to $157.90, inclusive.
( 4)  Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that becomes exercisable as to 3,748 shares on 02/14/2016, 3,747 shares on 02/14/2017, 02/14/2018 and 02/14/2019, and the remaining 3,119 shares on 02/14/2020.
( 5)  Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests on the fifth anniversary date (02/14/2020) of the grant.
( 6)  Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2016) of the date of grant.
( 7)  Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vested in five equal annual installments, beginning on the first anniversary date (02/14/2015) of the date of grant.
( 8)  Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested fully on 05/10/2006.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MCKEON BRIAN P
ONE IDEXX DRIVE
WESTBROOK, ME 04092

Executive VP, CFO & Treasurer

Signatures
Lily J. Lu, Attorney-in-Fact for Brian P. McKeon 2/18/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more IDEXX Laboratories Charts.
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more IDEXX Laboratories Charts.